CSF1R and glioblastoma: As such, in a proneural GBM model, CSF1R monotherapy by use of the blood–brain barrier permeable inhibitor BLZ945 displayed a decrease in M2‐polarized macrophages, whereas the total number of TAMs was unaltered (Pyonteck et al, 2013).